Literature DB >> 21454029

Diffusion-weighted MR imaging allows monitoring the effect of combretastatin A4 phosphate on rabbit implanted VX2 tumor model: 12-day dynamic results.

Haibo Shao1, Yicheng Ni, Xu Dai, Jian Zhang, Feng Chen, Guoguang Fan, Ziping Sun, Yaming Li, Hongxu Zhou, Ke Xu.   

Abstract

OBJECTIVES: To investigate the 12-day dynamic characteristics of tumor response to intravenous administration of CA4P in rabbit VX2 tumor models.
METHODS: Study protocol was approved by local ethical committee for animal care and use. Sixteen rabbits with 32 tumors on bilateral legs were randomly divided into treated and control groups. Conventional and DWI images were acquired before and 24 h, 4 days, 8 days and 12 days after treatment. The dynamic changes of tumor on images were correlated with histological results. ADCs were compared among and between groups at different time points.
RESULTS: The tumors in treated group grew slower than those in control group. In treaded group, the mean ADC decreased slightly at 24 h point due to cell edema caused by ischemia. Then, it increased significantly at 4 days and 8 days because of progressive central necrosis. Finally, peripheral tumor proliferation caused a second decrease of ADC at 12 days. The significant difference of ΔADC% between the two groups at 24 h, 4 days and 8 days indicated that the change of ADC in treated group was really caused by CA4P.
CONCLUSION: The dynamic histological changes of tumor caused by CA4P as reflected exactly by diffusion-weighted MR imaging indicate a noninvasive measure for monitoring tumor vascular targeting treatment.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21454029     DOI: 10.1016/j.ejrad.2011.03.009

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

1.  Biliary and duodenal drainage for reducing the radiotoxic risk of antineoplastic 131I-hypericin in rat models.

Authors:  Yue Li; Cuihua Jiang; Xiao Jiang; Ziping Sun; Marlein Miranda Cona; Wei Liu; Jian Zhang; Yicheng Ni
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-07

Review 2.  Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors.

Authors:  Li Liu; Devin O'Kelly; Regan Schuetze; Graham Carlson; Heling Zhou; Mary Lynn Trawick; Kevin G Pinney; Ralph P Mason
Journal:  Molecules       Date:  2021-04-27       Impact factor: 4.411

3.  Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models.

Authors:  Haibo Shao; Jian Zhang; Ziping Sun; Feng Chen; Xu Dai; Yaming Li; Yicheng Ni; Ke Xu
Journal:  Oncotarget       Date:  2015-06-10

4.  131I-Evans blue: evaluation of necrosis targeting property and preliminary assessment of the mechanism in animal models.

Authors:  Qiaomei Jin; Xin Shan; Qi Luo; Dongjian Zhang; Yuanyu Zhao; Nan Yao; Fei Peng; Dejian Huang; Zhiqi Yin; Wei Liu; Jian Zhang
Journal:  Acta Pharm Sin B       Date:  2017-09-19       Impact factor: 11.413

5.  Preclinical Evaluation of Radioiodinated Hoechst 33258 for Early Prediction of Tumor Response to Treatment of Vascular-Disrupting Agents.

Authors:  Dongjian Zhang; Meng Gao; Nan Yao; Cuihua Jiang; Wei Liu; Tiannv Li; Shaoli Song; Dejian Huang; Zhiqi Yin; Yunliang Qiu; Qiaomei Jin
Journal:  Contrast Media Mol Imaging       Date:  2018-02-26       Impact factor: 3.161

6.  Power Doppler ultrasound and contrast-enhanced ultrasound demonstrate non-invasive tumour vascular response to anti-vascular therapy in canine cancer patients.

Authors:  Eline Abma; Emmelie Stock; Ward De Spiegelaere; Leen Van Brantegem; Katrien Vanderperren; Yicheng Ni; Matthijs Vynck; Sylvie Daminet; Kaat De Clercq; Hilde de Rooster
Journal:  Sci Rep       Date:  2019-06-25       Impact factor: 4.379

7.  Treatment Effect of a Vascular-Disrupting Agent Dynamically Monitored by DWI: An Animal Experimental Study.

Authors:  Danping Huang; Ruimeng Yang; Yong Zou; Hongmei Lin; Xiangdong Xu; Xinhua Wei; Hanzheng Chang; Liqiong Wu; Wenshuang Ding; Wenjie Tang; Xinqing Jiang
Journal:  Can J Gastroenterol Hepatol       Date:  2021-12-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.